Aspirin-Myocardial Infarction Study (AMIS)
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Oct 27, 1999
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
It had been postulated that thrombosis plays a major role in the late stages of coronary artery occlusion. Platelet aggregation is a large component in the formation of arterial thrombi. Theoretically, an agent which prevents the aggregation of platelets would be of value in people with coronary artery disease. Aspirin, in small doses, inhibits platelet aggregation for prolonged periods of time, and therefore might be expected to prevent or retard the occlusion of coronary arteries. This would be reflected in a decrease in the incidence of myocardial infarction and a decrease i...
Gender
ALL
Eligibility criteria
- • Men and women, ages 30 to 69. Had a documented myocardial infarction.
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Allan Barker
Salt Lake Clinic Research Foundation
David Berkson
Unity Health Toronto
William Berstein
Icahn School of Medicine at Mount Sinai
Nemat Borhani
University of California, Davis
Elmer Cooper
Santa Rosa Medical Center
Leonard Dreifus
Lankenau Hospital
Noble Fowler
University of Cincinnati
Phillip Frost
USPHS Hospital
Mario Garcia-Palmieri
University of Puerto Rico Medical Science Campus
Hugh Gilmore
University of Miami
Sidney Goldstein
Henry Ford Hospital
Olga Haring
Northwestern University
J. Hoover
University of Washington
Richard Hutchinson
University of Mississippi Medical Center
William Krol
University of Maryland at Baltimore
Peter Kuo
Rutgers Medical School
Charles, Laubach
Institute for Medical Education and Research
Bernard Lewis
Palo Alto Medical Research Foundation
Jessie Marmorston
University of Southern California
J. McNamara
Pacific Health Research Institute
Dayton Miller
U.S. Centers for Disease Control and Prevention
Thaddeus Prout
Greater Baltimore Medical Center
David Richardson
Virginia Commonwealth University
Jorge Rios
George Washington University
Paul Samuel
Long Island Jewish-Hillside Medical Center
Stephen Scheidt
Weill Medical College of Cornell University
Robert Schlant
Emory University
Henry Schoch
University of Michigan
James Schoenberger
Rush University Medical Center
Marvin Segal
MOUNT SINAI HOSPITAL
Pantel Vokonas
Boston Health and Hospitals Department
C. Williams
Ogden Research Foundation
Gary Wilner
Endeavor Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials